Close

FibroGen (FGEN) Misses Q3 EPS by 15c

Go back to FibroGen (FGEN) Misses Q3 EPS by 15c

FibroGen Reports Third Quarter 2018 Financial Results

November 8, 2018 4:02 PM EST

Roxadustat New Drug Applications under Review in China and JapanPhase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time

SAN FRANCISCO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics,  today reported financial results for the third quarter of 2018 and provided an update on the companys recent developments.

With new drug applications for roxadustat in anemia associated... More